Zevaskyn™ (prademagene zamikeracel) – New orphan drug approval
April 29, 2025 - Abeona Therapeutics announced the FDA approval of Zevaskyn (prademagene zamikeracel), for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Download PDF
